Gilead Sciences, Inc.
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Gilead Sciences, Inc. reported 9 stock positions worth $1.8 billion. Its top holding was Lakefront Biotherapeutic-ADR (LKFT) at 32.3% of the portfolio, followed by Arcellx (ACLX, 30.8%) and Arcus Biosciences (RCUS, 23.9%). Compared with Q2 2025, it sold out of 5 and added to 1. The biggest buy was Assembly Biosciences (ASMB, shares +104%) and the biggest sale an exit from Hookipa Pharma (HOOK).
- Most Recent 13F
- Q2 2026
- Location
- FOSTER CITY, CA
- CIK
- 0000882095
- Portfolio Value
- $1.8B (Q3 2025)
- SEC Filing
- 0001123292-25-000642 ↗ filed Nov 13, 2025
Holdings Value
Holdings 9 stocks · $1.8B
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 32.31% | 16,707,477 | $578.7M | No change |
| ACLX Arcellx Inc. | 30.80% | 6,720,803 | $551.8M | No change |
| RCUS Arcus Biosciences Inc. | 23.86% | 31,424,760 | $427.4M | No change |
| ASMB Assembly Biosciences Inc. | 6.44% | 4,505,391 | $115.3M | Add +103.9% |
| MRUS Merus NV | 2.38% | 452,527 | $42.6M | No change |
| TNGX Tango Therapeutics Inc. | 2.28% | 4,854,443 | $40.8M | No change |
| KYTX Kyverna Therapeutics Inc. | 1.38% | 4,126,119 | $24.8M | No change |
| XLO Xilio Therapeutics Inc. | 0.43% | 9,105,451 | $7.7M | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.13% | 5,319,148 | $2.4M | No change |
Portfolio Sells Q2 2025 → Q3 2025
| HOOK Hookipa Pharma Inc. | Sold out | 0.00% | −0.18 |
| ALLO Allogene Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| KLRS Kalaris Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| IKENA ONCOLOGY INC | Sold out | 0.00% | −0.04 |
| BRNS Barinthus Biotherapeutics PL | Sold out | 0.00% | −0.01 |
Portfolio Buys Q2 2025 → Q3 2025
| ASMB Assembly Biosciences Inc. | Add +103.9% | 6.44% | +3.31 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.6B | RCUS, LKFT, ASMB, KYTX, XLO |
| Q1 2026 | 6 | $2.1B | ACLX, RCUS, LKFT, ASMB, KYTX |
| Q4 2025 | 6 | $1.9B | RCUS, LKFT, ACLX, ASMB, KYTX |
| Q3 2025 | 9 | $1.8B | LKFT, ACLX, RCUS, ASMB, MRUS |
| Q2 2025 | 14 | $1.3B | LKFT, ACLX, RCUS, ASMB, TNGX |
| Q1 2025 | 14 | $1.2B | ACLX, LKFT, RCUS, ASMB, MRUS |
| Q4 2024 | 16 | $1.6B | ACLX, LKFT, RCUS, ASMB, MRUS |